CoChat

Gene therapy improves motor and mental function of aromatic l-amino acid decarboxylase deficiency

Open access

The DOI matches its Crossref record; 53 of the 54 references it cites were found in a registry or an index.

Abstract

In patients with aromatic l-amino acid decarboxylase (AADC) deficiency, a decrease in catecholamines and serotonin levels in the brain leads to developmental delay and movement disorders. The beneficial effects of gene therapy in patients from 1 to 8 years of age with homogeneous severity of disease have been reported from Taiwan. We conducted an open-label phase 1/2 study of population including adolescent patients with different degrees of severity. Six patients were enrolled: four males (ages 4, 10, 15 and 19 years) and one female (age 12 years) with a severe phenotype who were not capable of voluntary movement or speech, and one female (age 5 years) with a moderate phenotype who could walk with support. The patients received a total of 2 × 1011 vector genomes of adeno-associated virus vector harbouring DDC via bilateral intraputaminal infusions. At up to 2 years after gene therapy, the motor function was remarkably improved in all patients. Three patients with the severe phenotype were able to stand with support, and one patient could walk with a walker, while the patient with the moderate phenotype could run and ride a bicycle. This moderate-phenotype patient also showed improvement in her mental function, being able to converse fluently and perform simple arithmetic. Dystonia disappeared and oculogyric crisis was markedly decreased in all patients. The patients exhibited transient choreic dyskinesia for a couple of months, but no adverse events caused by vector were observed. PET with 6-[18F]fluoro-l-m-tyrosine, a specific tracer for AADC, showed a persistently increased uptake in the broad areas of the putamen. In our study, older patients (>8 years of age) also showed improvement, although treatment was more effective in younger patients. The genetic background of our patients was heterogeneous, and some patients suspected of having remnant enzyme activity showed better improvement than the Taiwanese patients. In addition to the alleviation of motor symptoms, the cognitive and verbal functions were improved in a patient with the moderate phenotype. The restoration of dopamine synthesis in the putamen via gene transfer provides transformative medical benefit across all patient ages, genotypes, and disease severities included in this study, with the most pronounced improvements noted in moderate patients.10.1093/brain/awy331_video1awy331media15991361892001.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/brain/awy331

Cites

53 of 53 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 AIMS. The AIMS score of each patient was plotted. Before gene therapy, Patients 1, 4, 5 and 6 had a score of 0, Patient 2 had a score of 1, and Patient 3 had a score of 52. The scores of all patients improved. At 12 months, the score of Patient 3 reached 58, which represents the maximum score on this scale.
Figure 1 AIMS. The AIMS score of each patient was plotted. Before gene therapy, Patients 1, 4, 5 and 6 had a score of 0, Patient 2 had a score of 1, and Patient 3 had a score of 52. The scores of all patients improved. At 12 months, the score of Patient 3 reached 58, which represents the maximum score on this scale.CC BY-NC · PubMed Central
Figure 2 The evaluation of the mental development using Kyoto Scale of Psychological Development. The Cognition-Adaptation (C-A) and Language-Sociality (L-S) scores for the Developmental Quotient before and after gene therapy in Patient 3: moderate phenotype (A and B), and Patients 1, 2 and 4: severe phenotype (C and D). (A) Before treatment, the Language-Sociality score of Patient 3 was 42; this improved to 84. A Developmental Quotient score over 70 is in the normal range. (B) The Cognition-Adaptation score of Patient 3 improved from 50 to 66. (C and D) The pretreatment scores of the severe patients were almost 0 but showed mild improvement.
Figure 2 The evaluation of the mental development using Kyoto Scale of Psychological Development. The Cognition-Adaptation (C-A) and Language-Sociality (L-S) scores for the Developmental Quotient before and after gene therapy in Patient 3: moderate phenotype (A and B), and Patients 1, 2 and 4: severe phenotype (C and D). (A) Before treatment, the Language-Sociality score of Patient 3 was 42; this improved to 84. A Developmental Quotient score over 70 is in the normal range. (B) The Cognition-Adaptation score of Patient 3 improved from 50 to 66. (C and D) The pretreatment scores of the severe patients were almost 0 but showed mild improvement.CC BY-NC · PubMed Central
Figure 3 FMT-PET findings. The expression of AADC was detected by PET after the injection of FMT, the specific tracer for AADC. (A) The co-registered PET and MRI data before treatment. No signal was detected in their brains. (B) At 6 months after treatment (at 3 months after in Patient 5 alone), a high-intensity signal was detected in the bilateral putamen in all patients. (C) The signal in the putamen was maintained after 2 years in all patients.
Figure 3 FMT-PET findings. The expression of AADC was detected by PET after the injection of FMT, the specific tracer for AADC. (A) The co-registered PET and MRI data before treatment. No signal was detected in their brains. (B) At 6 months after treatment (at 3 months after in Patient 5 alone), a high-intensity signal was detected in the bilateral putamen in all patients. (C) The signal in the putamen was maintained after 2 years in all patients.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 53 references

Research works printed but not linked: 1

  1. Vitek, 1999, Neuronal activity in the basal ganglia in patients with generalized dystonia and hemiballismus, Ann Neurol, 46, 22, 10.1002/1531-8249(199907)46:1<22::AID-ANA6>3.0.CO;2-Z · doi:10.1002/1531-8249(199907)46:1<22::aid-ana6>3.0.co;2-z

Cited by

Metadata

Authors
Kojima, K., Nakajima, T., Taga, N., Miyauchi, A., Kato, M., Matsumoto, A., Ikeda, T., Nakamura, K., Kubota, T., Mizukami, H., Ono, S., Onuki, Y., Sato, T., Osaka, H., Muramatsu, S.-I., & Yamagata, T.
Affiliations
  • Jichi Medical University (JP)
  • Yamagata University (JP)
  • Anjo Kosei Hospital (JP)
  • Utsunomiya Central Clinic, Utsunomiya, Tochigi, Japan
Corresponding author
Yamagata, Takanori
Venue
Brain
Published
2019-01-23
Volume
142
Issue
2
Pages
322-333
ISSN
  • 0006-8950 (ISSN-L)
  • 1460-2156
OpenAlex
W2912202854
Cited by
139
References
54
Citations by year
2026: 10 · 2025: 11 · 2024: 14 · 2023: 23 · 2022: 23 · 2021: 34 · 2020: 18 · 2019: 6
FWCI
8.89
Type
journal article
Language
en
Open access
Locations
  • Brain (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Funders
  • Agency for Medical Research and Development
  • AMED (JP17ek0109168)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
  • Health Sciences › Medicine › Genetics (clinical) › Lysosomal Storage Disorders Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Metabolism and Genetic Disorders
Keywords
aromatic L-amino acid decarboxylase deficiency, gene therapy, adeno-associated virus vectors, motor function, cognitive function, dystonia, oculogyric crisis, dopamine synthesis, putamen, developmental delay, movement disorders
MeSH terms
Adolescent, Amino Acid Metabolism, Inborn Errors, Aromatic-L-Amino-Acid Decarboxylases, Brain, Child, Child, Preschool, Female, Humans, Male, Mental Processes, Motor Skills, Genetic Therapy, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.